Key result
Between 1994-1995 and 1998-1999, discharge beta-blocker prescription for Medicare patients with AMI increased from 50.3% to 70.7% (P<0.001), alongside improvements in other evidence-based therapies.
Why the study?
Did evidence-based process of care measures improve for Medicare patients hospitalized with acute myocardial infarction between 1994-1995 and 1998-1999?
Observational (n=270,467)
Yes
Did evidence-based process of care measures improve for Medicare patients hospitalized with acute myocardial infarction between 1994-1995 and 1998-1999?
Absolute Event Rate: 70.7% vs 50.3%
p-value: p=<.001
Between 1994 and 1999, there were significant national improvements in the prescription of guideline-directed medical therapies for Medicare patients with AMI, though substantial variations and gaps in care remained.
No takes yet. Share an insight, caveat, or question.
Gains in AMI evidence-based therapies support quality monitoring; extends national cohort trends but leaves outcome impact open.
Burwen et al. (2003) conducted an observational in Acute myocardial infarction (AMI) (n=270,467). Care in 1998-1999 vs. Care in 1994-1995 was evaluated on Discharge beta-blocker prescription (p=<.001). Between 1994-1995 and 1998-1999, discharge beta-blocker prescription for Medicare patients with AMI increased from 50.3% to 70.7% (P<0.001), alongside improvements in other evidence-based therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: